Memantine Aurobindo (Memantine Hydrochloride)

Memantine Hydrochloride is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function.

• Alzheimer’s disease (mild to moderate): improves cognitive performance and daily living activities.
• Alzheimer’s disease (moderate to severe): helps maintain functional abilities and slows decline.
• Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression associated with the condition.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor-associated ion channel, it blocks excessive calcium influx caused by prolonged glutamate activation, thereby reducing excitotoxic neuronal injury and supporting neuronal survival in Alzheimer’s disease.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Headache: mild to moderate cranial pain.
• Constipation: reduced bowel movements.
• Nausea: feeling of queasiness.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention.
• Seizures: occurrence of convulsive episodes.
• Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening.
• Hepatic failure: impaired liver function.
• Suicidal thoughts: emergence of depressive or suicidal ideation.

Before initiating therapy, clinicians should consider several safety factors.

• Renal impairment: assess kidney function and adjust dose if needed.
• History of seizures: monitor closely for new seizure activity.
• Cardiovascular disease: evaluate risk of arrhythmias.
• Concomitant NMDA antagonists: avoid combined use to prevent additive effects.
• Pregnancy: use only if the potential benefit justifies the potential risk to the fetus.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase adverse effects.
• Other NMDA receptor antagonists: combined use can lead to excessive inhibition.
• Strong CYP450 inhibitors (e.g., ketoconazole): may raise memantine plasma levels.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may diminish cognitive benefits of memantine.
• Diuretics: can alter renal clearance and affect drug concentration.
• Alcohol: may exacerbate dizziness and CNS depression.